MORGAN STANLEY - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H203. A total of 23 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
MORGAN STANLEY ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2022$7,000
-30.0%
10,611
+5.9%
0.00%
Q2 2022$10,000
-52.4%
10,023
-32.1%
0.00%
Q1 2022$21,000
+40.0%
14,763
+421.7%
0.00%
Q4 2021$15,000
-37.5%
2,830
-32.9%
0.00%
Q3 2021$24,000
-87.0%
4,219
-86.7%
0.00%
Q2 2021$184,000
+2200.0%
31,668
+2179.9%
0.00%
Q1 2021$8,000
-42.9%
1,389
-49.9%
0.00%
Q4 2020$14,0002,7720.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q1 2022
NameSharesValueWeighting ↓
Samjo Capital LLC 404,963$563,0000.48%
Cowen Prime Advisors LLC 332,197$462,0000.19%
ARMISTICE CAPITAL, LLC 834,054$1,159,0000.02%
Nantahala Capital Management 285,963$397,0000.02%
HighMark Wealth Management LLC 6,966$10,0000.01%
UBS Group AG 4,000$6,0000.00%
OSAIC HOLDINGS, INC. 13$00.00%
WELLS FARGO & COMPANY/MN 41$00.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
GEODE CAPITAL MANAGEMENT, LLC 46,039$63,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders